Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5874074 | 0.91 | ESR1 (0.48) | ESR1ESR2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL5780558 | 0.85 | ESR1 (0.43) | ESR1ESR2L3MBTL1ALDH1A1LMNA | |
| SCHEMBL5782401 | 0.85 | ESR1 (0.40) | ESR1ESR2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL720157 | 0.79 | ESR1 (0.53) | ESR1ESR2ALDH1A1HPGDMAPT | |
| SCHEMBL5783454 | 0.79 | ESR1 (0.47) | ESR1ESR2CYP11B2PKM | |
| SCHEMBL5441574 | 0.78 | HTR2A (0.52) | L3MBTL1ALDH1A1LMNAGPR35MAPT | |
| Chloroform SCHEMBL3708759 | 0.78 | ESR1 (0.49) | ESR1ESR2HPGDPKMMEN1 | |
| SCHEMBL169052 | 0.77 | ESR1 (0.44) | ESR1ESR2ALDH1A1LMNAHPGD | |
| SCHEMBL13076095 | 0.77 | ESR1 (0.45) | ESR1ESR2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL117485 | 0.77 | ESR1 (0.48) | ESR1ESR2L3MBTL1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487801-B1 | 7-ARYLSULFONAMIDO-2,3,4,5-TETRAHYDRO-1H-BENZO¬D|AZEPINE DERIVATIVES WITH 5-HT6 RECEPTOR AFFINITY FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LTD (GB) | 2006-04-19 | — | — | EP | disclosed |
| US-20050090485-A1 | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090485-A1 | 7-Arylsulfonamido-2,3,4,5-tetrahydro-1h-benzo'diazepine derivatives with 5ht6 receptor affinity for the reatment of cns disorders | HTR6, HTR7, HTR2A | ESR1 2161/4885ESR2 794/4885L3MBTL1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.